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ABSTRACT 
Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by hyperproliferation in 
the myeloid lineages of the bone marrow, leading to increased levels of circulating mature blood cells 
from one or more lineages.  MPNs consist of polycythemia vera, essential thrombocythemia and 
primary myelofibrosis. Several recurrent mutations are seen in MPNs, most of them resulting in an 
activation of the JAK/STAT signaling pathway. Telomeres are non-coding repetitive sequences of 
DNA located at the end of chromosomes. The telomeres are shortened with every cell division and 
when they become critically short, the cells enter a permanent growth arrest state called replicative 
senescence. When the telomeres are very short, the cells become genetically unstable and are more 
susceptible to genetic aberrations. There is accumulating evidence for a role for telomere 
dysregulation in the pathogenesis of MPNs and AML, and the overall aim of the studies included in 
this thesis was to better define this role.  
To clarify a potential dysregulation of telomeres and telomere associated proteins in MPNs, we 
studied the telomere length (TL), TERT expression and expression of telomere associated proteins in 
81 patients with MPNs and 43 healthy controls. We found that patients with MPNs have shorter 
telomeres in their granulocytes compared to that of healthy controls, but also compared to the patients’ 
own lymphoid cells. There was no difference in TERT expression between patients and controls. The 
expression of two positive regulators of TL was lower, and the expression of two negative regulators 
of TL was higher in patients with MPNs. The dysregulation of telomere binding proteins may 
contribute to the telomere shortening seen in MPNs.  
Genetic variants in the TERT locus are implicated in susceptibility to cancer and other diseases. Recent 
reports also revealed an association between the SNP TERT rs2736100_CC genotype and the risk of 
developing MPNs in Caucasian populations. We genotyped patients and healthy controls from Sweden 
and China and found that the TERT rs2736100_C allele is associated with an increased risk of MPN 
development in both populations. The association of the C-allele with an increased risk of MPNs was 
only seen in male MPN patients, who generally have a worse outcome than female MPN patients. 
Moreover, the Chinese healthy population had significantly lower frequency of the TERT 
rs2736100_C allele compared to their Swedish counterpart, which may contribute to the lower MPN 
incidence seen in China compared to that in Europe. Patients with the TERT rs2736100_CC had the 
highest TERT expression, which may make them more susceptible to develop MPNs.   
The evolution of an acute promyelocytic leukemia (APL)-clone in a patient with a very late relapse 
was studied to distinguish between a relapse of the first APL, a secondary APL or a second de novo 
APL, and thereby guide future treatment decisions. Based on identical breakpoints of the PML-RARα 
gene, but differences in genetic aberrations and mutations in the FLT3-gene, we conclude that the 
patient most likely suffered a true relapse of her initial APL. We hypothesize that the PML-RARα- 
bearing pre-leukemic clone survived the initial chemotherapy and did not develop into an APL until 
seventeen years later, when the clone acquired another FLT3 mutation and other genetic aberrations.  
JAK2 inhibitors have proven effective in reducing symptoms and splenomegaly in patients with 
myelofibrosis, but they do not eliminate the disease initiating clones. A telomerase inhibitor is in 
clinical trials for MF with promising results, but with severe myelosuppression as a side-effect. We 
studied the effect of the JAK2 inhibitor LY2784544 in combination with the telomerase inhibitor 
GRN163L in a JAK2
V617F
 –bearing erythroleukemia cell line. The combination had a larger effect on 
viability and number of cells than either of the drugs alone. Treatment with LY2784544 alone 
increased the fraction of HEL cells expressing the stem cell marker CD34, an effect that was partially 
mediated by an up-regulation of the transcription factor KLF4. Importantly, accumulation of CD34 
positive cells was not seen after combined LY2784544/GRN163 treatment. This suggests that 
combining JAK2- and telomerase inhibition may have a therapeutic benefit, and that KLF4 may be a 
potential therapeutic target in MPNs. Furthermore, JAK2 inhibition reduced the telomerase activity, 
indicating a direct effect of JAK/STAT signaling on telomere regulation in MPNs.   
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1 INTRODUCTION 
1.1 TELOMERES AND TELOMERE MAINTENANCE 
1.1.1 Telomeres 
Telomeres are nucleoprotein structures located at the chromosome ends and consist of up to 
20 kb tandemly repeated TTAGGG sequences and associated proteins
1
. The telomeres are 
arranged in loop structures that are stabilized by associated proteins. The six key proteins 
binding to the telomere are TRF1, TRF2, TIN2, POT1, TPP1 and RAP1, which together form 
structures, the shelterin complex (figure 1), around the nucleotide sequence
2
. The telomere 
and its associated proteins form protective caps on human chromosome ends and prevents 
them from being recognized as double strand breaks
3
. They are thus essential for maintaining 
genomic stability and integrity.  
DNA polymerase can only replicate in the 5’ → 3’ direction in the replication fork, which 
renders it unable to elongate the end of the lagging strand
4
 (figure 2). This ‘end replication 
problem’ results in progressive telomere shortening, with approximately 50 - 100 bases for 
every DNA replication
5,6
. The rate of telomere shortening is also affected by environmental 
Figure 1. Telomere structure. Upper picture show how the telomere binding proteins 
interact with the telomeric DNA in an open state. Lower picture shows a closed 
telomeric structure that is hold together by the telomere binding proteins.  
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factors
7
. When a telomere reaches a critical length, it activates a DNA damage response and 
triggers the cell to enter a permanent growth arrest stage called replicative senescence. 
Senescence mediated by telomere shortening is suggested as an anti-tumor mechanism, but 
also contributes to the aging of mitotic tissues
8
. The telomere length (TL) in normal human 
cells varies between 5-15 kb
9
. Many factors influence the TL and telomere maintenance is a 
delicate dynamic process of lengthening and erosion.  
 
1.1.2 Telomere binding proteins 
The shelterin proteins are crucial for telomere protection and maintenance. They govern and 
stabilize the 3D structure of the telomeric sequence
2
. TRF1 and TRF2 bind directly to the 
double stranded telomeric sequence whereas POT1 binds directly to the single stranded 
overhang of telomeres
10
. The other shelterin proteins interact indirectly with telomeric DNA 
by binding to TRF1, TRF2 or POT1 (figure 1). Shelterin proteins affect telomerase function 
and protect telomeres from DNA damage responses by inhibiting ATM and ATR dependent 
pathways
11
. Shelterin proteins are thought to mainly affect telomerase function by regulating 
its access to the telomeres. One of these shelterins, POT1, is a negative regulator of TL and 
the depletion of POT1 from the single strand overhang results in excessive telomere 
lengthening
12
. In contrast to POT1, TPP1 is essential for recruiting telomerase to the 
telomeres, and certain mutations in TPP1 result in excessive telomeric loss
13
.  
3’ 
Figure 2. Illustration of the end replication problem. Replication of the lagging strand 
occurs stepwise. The primers (yellow) required for initiation of replication by polymerase 
are degraded and the gap filled in. The space where the outermost primer binds (orange) 
cannot be filled in and the telomere is shortened. 
5’ 
3’ 
3’ 
5’ 
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1.1.3 Telomerase 
Telomerase is an enzyme that can synthesize the telomeric sequence and hence lengthen 
telomeres. Telomerase consists of two core components; the rate-limiting catalytic subunit 
TERT and a RNA template for telomeric DNA called TER
14
. Telomerase is very tightly 
regulated and only active in cells in need of extensive proliferation potential, such as activated 
lymphocytes, stem cells and embryonic tissues
15
. The main regulator of telomerase activity is 
the expression of TERT
15
. Ectopic expression of TERT is enough to induce telomerase 
activity, suggesting that TERT is the rate limiting component of telomerase
16
.  
The positive relationship between cellular life-span and telomere length and telomerase 
expression has been well established
17
. Stem/progenitor cells with great proliferation potential 
have a higher expression of telomerase to be able to compensate for the telomere loss during 
cell divisions
18
. Impaired telomere maintenance or telomerase deficiency may lead to 
defective hematopoietic cell proliferation and bone marrow failure, while aberrant activation 
of telomerase is essential for immortalization and transformation of human cells including 
hematopoietic cells
19
.  
1.1.4 Regulation of TERT expression 
The TERT gene is localized at chromosome 5p15.33 and is mainly regulated at a 
transcriptional level
15,20
. The TERT promotor is extensively studied and binding sites for an 
abundance of both activating and suppressing transcription factors have been identified. There 
are many activating factors, such as c-Myc, HIF-1, AP2 and ER, and suppressing factors 
include mostly tumor suppressors, such as p53, WT1, and Menin
21
. TERT transcription is 
highly influenced by the general transcription factor SP1 that binds to the TATA binding 
motif
21
. Interestingly, no TATA box has been found in the TERT promoter, yet mutations 
affecting SP1 binding sites can attenuate or even eliminate TERT promoter activity
22
.  
TERT is also regulated post-transcriptionally by alternative splicing. Seven mRNA variants 
have been identified, but only the full length transcription variant is translated into a 
functional protein
23,24
. Phosphorylation of TERT can either activate or suppress TERT, 
depending on which site is phosphorylated
25
. Telomerase can be inactive in cells despite the 
presence of full length TERT mRNA, suggesting that posttranscriptional regulation of TERT 
potentially plays an important role
26,27
. The TERT promoter harbors one CpG island and 
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epigenetic regulation of TERT is evident in differentiation and in cancers
28
. There are 
conflicting data regarding the association between methylation status of the TERT promoter 
and TERT expression. Some authors report that TERT expression is activated upon promoter 
demethylation
29
, whereas others describe an activation of TERT  upon hypermethylation of 
the promoter
30,31
. It is also proposed that the TERT promoter is highly regulated by histone 
modifications, including repression by hypoacetylation of core histones
32-34
. Apart from 
TERT regulation, histone modifications and methylation of the subtelomeric region have also 
been shown to play a role in regulating TL
35
.  
1.1.5 Alternative lengthening of telomeres 
Some tumors do not express telomerase but still have an unlimited replicative potential and 
the ability to maintain their telomeres
36,37
. In these cells, telomeres are lengthened by 
recombination, often called alternative lengthening of telomeres (ALT) (figure 3)
38
. This 
mechanism for telomere lengthening is mostly found in sarcomas and high grade 
astrocytomas
36,39
. Telomere lengthening with ALT is more prone to functional errors than 
lengthening by telomerase
40
. ALT typically causes a great variation in TL within an 
individual cell, ranging from atypically long to undetectably short
41
. It is debated whether 
telomerase activity and ALT are mutually exclusive, but there is evidence that they can 
coexist and that ALT can be induced if telomerase activity is repressed
42
.  
 
 
 
 
 
 
Figure 3. Illustration of alternative lengthening of telomeres. (2) The 3’ end of telomere B 
places itself alongside telomere A and is elongated, using telomere A as a template. (3) This 
elongation of the B telomere’s 3’ end enables the synthetization of its complementary strand.  
5’ 
3’ 
3’ 
5’ 
A 
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B 
A 
B 
1 
2 
3 
5 
 
1.1.6 Telomeres and telomerase in in human diseases 
Telomere dysfunction have been shown to play a role in many different diseases, from 
depression
43
 to rheumatoid arthritis
44
, but telomere biology has mostly been highlighted in 
malignant tumors. In order for a malignant cell to obtain indefinite dividing capacity, it must 
acquire the ability to elongate its telomeres. In the vast majority of tumors this is 
accomplished by activating telomerase, which has been shown to be detectable in 90% of all 
tumor types
45-47
. The other 10% are thought to elongate their telomeres by ALT or other 
similar mechanisms
40
. Telomerase activation is thus necessary for the development of several 
cancer types
48-50
, but activation of telomerase alone is not sufficient for malignant 
transformation
51,52
. Even though telomerase is aberrantly expressed in most tumor cells, these 
often have shorter telomeres
53
. This could be secondary to tumor cells’ high proliferation 
resulting in accelerated telomere erosion, which cannot be fully compensated by telomerase 
activity. Alternatively, cancer may originate from cells having short telomeres have bypassed 
replicative senescence and are genetically instable (figure 4).  
Abrogation of  
  tumor suppressor  
     pathways and loss  
      of cell cycle  
        control 
Cancer cell with 
unlimited proliferative 
potential 
Telomerase 
activity or ALT 
Genetically unstable 
cell with uncapped 
telomeres 
Cell death 
Cell in replicative 
senescence with 
short telomeres 
Normal 
dividing cell 
Multiple 
replications and 
telomere 
shortening 
Figure 4. Illustration of telomere shortening and how malignant transformation can occur 
when cells manage to bypass replicative senescence. Italic text describes events whereas 
bold text describes the state of the cell. 
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Growing amount of data supports the notion that telomerase has an active role in 
tumorigenesis independent of its telomere lengthening function
54,55
. This role is so far 
undefined, but a possible contributing mechanism could be that TERT make cells more 
resistant to apoptosis
56,57
. Despite strong evidence for telomerase being a key player in 
tumorigenesis, its activation has also been proposed to mitigate genomic instability in tumor 
cells caused by shorter and dysfunctional telomeres
53
. Several mutations in the telomere 
associated genes have been linked to tumors and other diseases. For example, germline 
mutations in the TERT promoter and inactivating mutations in POT1 have recently been 
associated with familial melanoma
58-60
, and mutations in TPP1 have recently been shown to 
cause bone marrow failure including aplastic anemia
61
.  
 
1.2 MYELOPROLIFERATIVE NEOPLASMS 
Myeloproliferative neoplasms (MPNs) are a group of clonal disorders within the myeloid 
lineages of the bone marrow (BM). MPNs are characterized by hyperproliferation, resulting in 
excessive numbers of terminally differentiated cells from one or more of the myeloid 
lineages. MPNs consist of polycythemia vera, essential thrombocythemia, and primary 
myelofibrosis. The incidence of MPNs varies between different parts of the world, with a 
higher incidence in Europe (5.8/100 000)
62,63
 compared to East Asia (2/100 000)
64
.  The 
acquired mutation JAK2
V617F
 and mutations in JAK2 exon 12, Calreticulin (CALR) and MPL 
are found in the majority of patients with MPNs (see chapter 1.2.4).  
1.2.1 Polycythemia vera  
Polycythemia vera (PV) is characterized by excessive proliferation in the erythroid lineage 
leading to a high number of mature erythrocytes in the peripheral blood. In Sweden PV has an 
incidence of 1.9-2.6/ 100 000 persons/year
65,66
. The median age at diagnosis is 70 years and 
the condition affects men and women equally. Symptoms include fatigue, pruritus, head ache, 
sleeping difficulties and blushing
67
. Patients have a hypercellular BM dominated by 
erythropoiesis (figure 5). In many patients there is also hyperproliferation in other myeloid 
lineages, leading to high platelet and white blood cell counts
67
. PV is diagnosed according to 
the World Health Organization (WHO) 2008 classification system (table 1)
68,69
. Mutations in 
JAK2 are seen in the majority of patients with PV (see chapter 1.2.4). 
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The presence of both major criteria and one minor criterion or the presence of the first major 
criterion together with 2 minor criteria is required for diagnosis.  
 
Major criteria 
1. Hemoglobin >185g/L in men, >165g/L in women, or hematocrit >0.52 in men and >0.48 
in women, or other evidence of increased red cell volume* 
2. Presence of JAK2 
V617F
 or other functionally similar mutation such as the JAK2 exon 12 
mutation 
 
Minor criteria 
1. Bone marrow biopsy showing hyper cellularity for age with tri-lineage growth with 
prominent erythroid, granulocytic, and megakaryocytic proliferation 
2. Subnormal level of erythropoietin in serum 
3. Endogenous erythroid colony formation in vitro 
Table 1. The 2008 WHO classification system for diagnosis of PV
69
.  
Figure 5. Bone marrow from a patient with polycythemia vera showing a dominating 
erythropoiesis and large megakaryocytes. 
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1.2.2 Essential thrombocythemia 
Essential thrombocythemia (ET) is characterized by megakaryocyte proliferation resulting in 
an abnormally high platelet count. The symptoms are typically mild and ET is often 
discovered at a routine medical examination. ET is also diagnosed according to WHO criteria 
and requires that the patient has a high platelet count (>450  109/L), proliferating 
megakaryocytes seen in the BM (figure 6), and an absence of characteristic mutations causing 
secondary thrombocythemia (table 2). Patients with ET have an elevated risk for venous 
thromboembolism (VTE), but paradoxically also for hemorrhages at very high platelet counts 
(>1,500  109/L)70. The risk of progression to myelofibrosis (MF) and transformation to 
Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) is low (see chapter 
1.2.6). A majority of patients with ET carries mutations in JAK2, the thrombopoetin receptor 
MPL or C ALR (see chapter 1.2.4). 
 
Figure 6. Large mature megakaryocytes in the bone marrow from a patient with essential 
thrombocythemia. 
Table 2. The 2008 WHO classification system for diagnosis of ET
69
.  
All four major criteria have to be met for the diagnosis of ET.  
 
Major criteria 
1. Platelet count >450  109/L 
2. Proliferating megakaryocytes with large and mature morphology. No or insignificant 
granulocyte or erythroid proliferation.  
3. Not meeting the WHO criteria for any other myeloid neoplasm 
4. Presence of JAK2V617F or other clonal marker. If no marker is identified, all causes of reactive 
thrombocytosis have to be excluded.  
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1.2.3 Primary myelofibrosis 
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that is characterized by 
myeloproliferation, atypical megakaryocytes and BM fibrosis (figure 7)
71
. Diagnostic criteria 
are presented in table 3. Anemia and splenomegaly secondary to fibrosis of the BM are 
common. Symptoms include fatigue, night sweats and weight loss and the condition affects 
about 0.6/100 000 persons per year in Sweden
65
. As the name suggests, PMF does not 
develop from a preexisting hematological disease. However, the pathology is similar to 
secondary myelofibrosis derived from a previous ET or PV. PMF patients have an increased 
risk of VTE, but not as high as that of the patients with ET or PV. PMF has the worst 
prognosis of all MPNs and the median survival time after a PMF diagnosis is only 6 years
72
. 
 
 
Figure 7. Fibrosis in the bone marrow from a patient with primary myelofibrosis. 
 
Table 3. The 2008 WHO classification system for diagnosis of PMF
69
.  
All three major criteria and two minor criteria have to be met for the diagnosis of PMF.  
 
Major criteria 
1. Proliferating atypical megakaryocytes combined with either collagen and/or reticulin fibrosis.  
In the absence of fibrosis, the changes in megakaryocytes must be accompanied by a 
hypercellular bone marrow, granulocytic proliferation and often suppressed erythropoiesis 
(pre-fibrotic PMF).  
2. Not meeting the WHO criteria for any other myeloid neoplasm 
3. Presence of JAK2V617F or other clonal marker. If no marker is identified, causes of reactive 
myelofibrosis must be excluded.  
 
Minor criteria 
1. Leukoerythroblasts in the peripheral blood 
2. Elevated lactate dehydrogenase  
3. Splenomegaly 
4. Anemia 
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1.2.4 Molecular and cytogenetic background of myeloproliferative neoplasms 
In 2005 a gain of function mutation of Janus Kinase 2 (JAK2) in MPNs was described by 
several research groups simultanously
73-75
. The mutation leads to phenylalanine being 
substituted by valine at position 617 (JAK2
V617F
), making the kinase constitutively active. 
Normally when the ligand binds to the transmembrane receptor, the receptor undergoes 
conformational changes and the JAK2 phosphorylates the cytoplasmic region of the receptor. 
Upon activation, JAK2 also phosphorylates members of the STAT family of transcription 
factors which mediates the downstream intracellular signal
76
. However, when JAK2 is 
constitutively active a proliferation signal will be sent to the nucleus of the cells, even in the 
absence of the proper ligand-signal. The JAK2
V61F
 is present in 95% of PV-patients and 60% 
and 50% of ET- and PMF patients, respectively
77
. The presence on JAK2
V617F
 has been linked 
to an increased risk of secondary myelofibrosis in ET and PV patients
73,78
 and it is one of the 
risk factors for thrombosis in ET patients
79
. The reports regarding the clinical role of 
JAK2
V617F
 in PMF are somewhat contradictive, where some authors report a reduced overall 
survival when the mutation is present
80
, and others report that a low allele burden has been 
associated with shorter survival
81
.  
JAK2
V617F
 is the most common mutation in MPNs, but other recurrent mutations also exist. 
Mutations in exon 12 of the JAK2 gene is seen in 16% of PV patients without the JAK2
V617F
, 
and is more often seen in younger patients with a more isolated effect on the erythroid 
lineage
82-84
. About 5% of ET and PMF patients harbor activating mutations in the 
thrombopoietin receptor MPL (W515L or W515K), resulting in cytokine-independent growth 
mediated thorough the JAK/STAT signaling cascade
85
.  
Mutations in the CALR gene in 67-88% of JAK2
V617F
 and MPL mutation-negative ET and 
PMF patients were discovered in 2013 and these mutations also result in a hyperactivation of 
the JAK/STAT pathway
86,87
. Authors have reported that ET patients with CALR mutations 
have a prognostic advantage over those with the JAK2
V617F 
mutation
88
. Other more rare 
mutations have also been associated with MPNs (e.g. SOCS1-3, TET2, EZH2, ASXL1, and 
RUNX1) and most of them affect JAK/STAT signaling
89,90
. EZH2 and ASXL1 have been 
associated with an increased risk of disease progression, but the potential prognostic relevance 
of most of those mutations in MPNs is not yet known
91,92
.   
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Cytogenetic abnormalities can be found in 11%, 7% and 33% of patients with PV, ET and 
PMF, respectively
93-95
. Most frequent abnormalities are shared with other hematological 
malignancies, but +9 and del(13q) mainly occur in MPNs
96
. 
1.2.5 Treatment of myeloproliferative neoplasms 
PV is often treated with phlebotomy and low-dose aspirin. High-risk patients with ET are 
often also prescribed low-dose aspirin, but this should be avoided in patients with very high 
platelet count (>1,500  109/L) due to the risk of paradoxical bleeding.  High-risk PV and ET 
patients are often offered cytoreductive treatment with pegylated interferon-α (younger 
patients) or hydroxyurea (HU) (older patients)
97
. The treatment of PMF is focused on 
reducing symptoms. Patients with anemia often receive erythropoietin stimulation and 
patients with high blood cell counts get cytoreductive treatment
97
. Splenomegaly is often 
reduced by cytoreductive treatment, but can also be treated with JAK2 inhibitors or more 
rarely splenectomy. Allogeneic stem cell transplantation is considered in young patients with 
an intermediate or high-risk PMF.  
An abundance of JAK2 inhibitors are currently in clinical trials for MPNs. The most well 
studied and established inhibitor is ruxolitinib (Jakavi), which is now approved for 
treatment of PMF and refractory PV. Most JAK2 inhibitors also affect other targets than 
JAK2, but very little is known about how their effect on other targets influences their 
efficiency in treating MPNs. Interestingly, patients with and without mutations in JAK2 
benefit equally from JAK2 inhibition, suggesting a more general effect on the JAK/STAT 
pathway
89
. Even though JAK2 inhibitors are effective in reducing symptoms for many 
patients, they are not curative. Some JAK2 inhibitors are shown to reduce the JAK2
V617F
 
allele burden in a fraction of patients, but it does not seem to eliminate the disease clone
98,99
.  
The telomerase inhibitor GRN163L (Imetelstat) has been used in a clinical trial to treat MF. 
In one study, 21% of patients treated with GRN163L either had a complete remission (CR) 
(defined as normalization of hepatosplenomegaly, blood counts and leukocyte differential 
together with reversal of BM fibrosis) or a partial remission (defined with the same criteria as 
for complete remission apart from reversal of the BM fibrosis)
100
. It should be noted that 
some patients developed severe myelosuppression.  
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1.2.6 Transformation to myelofibrosis, myelodysplastic syndromes and acute 
myeloid leukemia 
Patients with PV and ET have a well-recognized risk of developing secondary MF. The risk 
of developing MF is reported to be 4.9 – 6% per 10 years for PV and 0.8 – 4.9% per 10 years 
for ET
101
.  
MPNs can also transform into MDS, which is a group of disorders with BM failure resulting 
in cytopenias and/or malfunction of the circulating mature cells, or into AML. The risk of 
transformation to MDS/AML is 5 – 10% per 10 years for PV and 2 – 5% per 10 years for 
ET
102
. Patients with PMF have the highest risk of transformation, 8 - 20% during a 10 year 
observation
102
. The molecular events driving this transformation are unclear. An AML 
secondary to a MPN is associated with a more complex karyotype, which is thought to 
contribute to the worse prognosis seen in these patients
103,104
.  Treatment of MPN with 
radioactive phosphorous (P
32
) and alkylators has been linked with an increased risk of 
transformation into AML
102,105,106
. Whether HU has a leukemogenic effect is still 
debated
102,107
, but 25% of MPN patients transforming to AML/MDS had no previous 
cytoreductive treatment
102
. 
Several recurrent mutations in MPNs, such as RUNX1, TP53, SRSF2, IDH1/2, IKZF1, NF1, 
NRAS, and DNMT3A, are linked to a higher risk for transformation
104,108-110
. Other risk factors 
for leukemic transformation are abnormal karyotypes, leukocytosis and reticulin fibrosis
111
. 
The most common mutation in MPNs, JAK2
V617F
, has not been linked to an increased risk for 
transformation into AML
112
. However an association between JAK2
V617F
 allele burden in PV 
and ET and the transformation to MF has been reported
113
. Interestingly, sometimes a 
JAK2
V617F
 positive MPN transforms into a JAK2
V617F
 negative AML, suggesting that the 
clone giving rise to the secondary AML is a more primitive one than the JAK2
V617F
 clone 
driving the MPN
114
.  
1.2.7 Telomeres in myeloproliferative neoplasms 
Telomere length in MPNs has been assessed by several research groups and shown to be 
shorter in cells from patients with MPNs compared to those of healthy individuals
115-117
. 
Authors have also reported that short telomeres in BM cells could predict progression of 
MPN
115
. The mechanism causing this telomere shortening and how telomere shortening 
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potentially contributes to the pathology and progression of MPNs is not understood. The 
telomerase activity is reported to be higher in the BM of MPN patients compared to that of 
healthy individuals
115,118
. Recently, a single nucleotide polymorphism (SNP) variant in the 
TERT promoter has been linked to the risk of MPN development
119,120
. Any association 
between telomerase activity and/or TL and prognosis in MPNs has so far not been established.  
 
1.3 ACUTE MYELOID LEUKEMIA 
AML is a common term for diseases characterized by clonal expansion of precursor cells of 
the myeloid lineage and a block in their differentiation (figure 8)
121
. The accumulation of 
immature cells and block in myeloid differentiation in the BM results in impaired normal  
hematopoiesis which causes anemia, thrombocytopenia and granulocytopenia.  
Diagnostic criteria for AML are the presence of ≥20% myeloblasts in the BM or even less if 
characteristic genetic aberrations are detected
68
. Historically, AML has been classified using 
the FAB-classification system described in table 4
122
. Today the WHO 2008 classification is 
used, which is based on the presence of genetic aberrations and is shown in table 5
68
. A 
Acute Myeloid leukemia Normal hematopoiesis 
Progenitor- and 
precursor cells  
Mature cells  
HSCs  
AML 
blasts 
LSCs 
Leukemic 
progenitors  
Myeloid 
cells 
Lymphoid 
cells 
Figure 8. Normal and leukemic hematopoiesis. Hematopoietic stem cells (HSCs) give rise to 
progenitor and precursor cells that are committed to specific hematopoietic lineages. Those 
cells later differentiate to become mature blood cells. Leukemic stem cells (LSCs) generate 
leukemic progenitors and the more differentiated, but still immature, leukemic blasts. 
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revision of this classification is underway. The incidence of AML increases with age to reach 
a maximum of 150/100 000 in individuals 80-85 year of age in Sweden
123
. The median age at 
diagnosis is approximately 70 years and AML is slightly more common among men than 
among women
121
.  
Table 4. French-American-British 
classification of acute myeloid leukemias 
 
M0: Acute myeloblastic leukemia, minimally 
differentiated 
M1: Acute myeloblastic leukemia, without 
maturation 
M2: Acute myeloblastic leukemia, with 
granulocytic maturation 
M3: Acute promyelocytic leukemia 
M4: Acute myelomonocytic leukemia 
M5: Acute monoblastic leukemia 
M6: Acute erythroid leukemias 
M7: Acute megakaryoblastic leukemia 
Table 5. WHO 2008 classification of acute 
myeloid leukemia 
 
 Acute myeloid leukemia with recurrent 
genetic abnormalities 
 AML with myelodysplasia-related changes 
 Therapy-related myeloid neoplasms 
 Myeloid Sarcoma 
 Acute myeloid leukemia,  not otherwise 
specified 
 Acute leukemia of ambiguous lineage 
 
The development of AML is a multi-step process in which several mutations and 
chromosomal abnormalities are aquired
124
. It has been proposed that both the acquisition of 
mutations that activate signaling pathways and give hematopoietic cells a proliferative 
advantage and mutations in transcription factors impairing hematopoietic differentiation are 
crucial for AML development
125
. Apart from transcription factors and genes involved in 
signaling pathways, tumor suppressors, splicing factors, and genes involved in DNA 
methylation are also frequently mutated in AML
121
.  There are many recurring mutations such 
as FLT3, C-KIT, N-RAS, RUNX1, WT-1 and ASXL1, to name but a few
121,126
. The variety of 
mutations seen in AML results in a very heterogeneous group of diseases. About one fourth of 
AMLs are secondary to other hematological diseases, such as MPNs or MDS, or previous 
treatment with chemo- or radiotherapy. 
A special case is the old M3 (FAB) class of leukemia, acute promyelocytic leukemia (APL), 
where 97% of the patients have a characteristic translocation resulting in the fusion protein 
PML-RARα which blocks the differentiation and drives proliferation at the promyelocytic 
stage
127,128
.  
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2 AIMS 
The overall aim of this PhD project was to better define the role of telomeres and telomerase 
in the pathogenesis of MPNs and AML. The specific aims for each paper are here described 
after their Roman numerals. 
I. The aim of this study was to assess the potential association between the expression of 
shelterin proteins and TL in MPN patients, in order to better understand the 
mechanism causing telomere shortening in MPN patients. Further, we aimed to define 
the influence of MPN subtype, JAK2
V617F
 mutation status, disease duration and 
therapy on telomere regulation in MPNs.  
II. Here our aim was to elucidate the potential relationship between TERT rs2736100 
genotypes and the risk of MPNs in two different ethnical populations with different 
incidences of MPNs. We also sought to determine how the different rs2736100 
genotypes influence TL and TERT expression in MPN patients.  
III. In this paper we aimed to define the clonal evolution in a patient with APL who after 
17 years of clinical remission presented with the same disease. The goal was to 
elucidate whether this patient suffered a true APL relapse, a secondary APL or a 
second de novo APL, and thereby guide treatment decisions. 
IV. This study was designed to outline the effect of the JAK2 inhibitor LY2784544 in the 
JAK2
V617F
-bearing cell line HEL, in order to better understand why MPN patients 
have a limited response to JAK2 inhibitors. Secondly, we wanted to reveal how the 
telomerase inhibitor GRN163L achieves its therapeutic effect in MPNs. We also 
sought to determine whether combined inhibition of JAK2 and telomerase can have a 
synergistic therapeutic effect in MPNs.  
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3 METHODS  
3.1 PATIENT SAMPLES (PAPERS I-III) 
Peripheral blood from patients diagnosed with MPN was taken at the outpatient clinic at the 
Karolinska University Hospital in Solna (papers I & II) and at Qilu Hospital, Shandong 
University, Jinan, China (paper II). The APL patient studied in paper III was sampled and 
treated at the Karolinska University Hospital in Solna. Informed consent was registered from 
all patients and the studies were approved by regional ethics committees in Stockholm and in 
Shandong. Erythrocytes were removed, using Hetasep, from the samples collected in Sweden, 
whereafter mono- and polynuclear cells were separated with Ficoll-Hypaque density gradient 
centrifugation. Whole blood from the Swedish patients was also prepared for flow-FISH (see 
3.4). 
3.2 CELL LINES AND CULTURE CONDITIONS (PAPERS I & IV) 
All cell lines used in this thesis were purchased from DSMZ. The HEL cell line was 
established in 1980 from the peripheral blood of a 30 year old man diagnosed with acute 
erythroleukemia
129
. The HEL cell line is homozygous for the JAK2
V617F 
mutation and displays 
cytogenetic abnormalities with loss of long-arm material from both chromosome 5 and 
7
130,131
. HEL cells were cultured in RPMI1640 supplemented with 10% FBS, 2mM L-
glutamine and 100U/ml penicillin-streptomycin and kept at a density of 0.2-1.2  106/ml. 
When treating cells with drugs (chapter 3.3), medium and drugs were changed every other 
day.  
3.3 DRUGS (PAPERS I & IV) 
In this project the JAK2 inhibitor LY2784544 (Gandotinib) was used. This inhibitor was 
chosen because of its concentration dependent selectivity for JAK2
V617F
. LY2784544 is 
reported to have an IC50 of 55nM for inhibiting JAK2
V617F
 driven proliferation compared to 
an IC50 of 2.26 µM for wild-type JAK2
132
. A phase I trial on 38 patients (31 MF, 6 PV, 1 ET) 
showed that a daily dose of 120 mg/day was well tolerated. Higher doses led to a substantial 
increase in serum creatinine. Three of the 10 patients receiving the 120 mg daily dose 
achieved clinical improvement. Across all dosage levels, 56% of the patients scored a >50% 
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improvement in their total symptom score (assessed by the Myeloproliferative Neoplasm 
Symptom Assessment Form
133
)
134
. Phase II trials are now ongoing.  
The telomerase inhibitor GRN163L (Imetelstat) was used in these papers. GRN163L is an 
oligonucleotide with the complementary sequence to the RNA component of telomerase and 
binds to it with high affinity.  The component also has a thio-phosphoramidate backbone 
which makes it more resistant to nucleases and increases its affinity to TER.  
3.4 FLOW-FISH OF TELOMERE LENGTH (PAPERS I, II & IV) 
The average TL was assessed with flow-FISH according to the protocol by Baerlocher et al
135
 
with some modifications. Calf thymocytes were kindly donated from Ö-slakt AB and included 
in all samples as positive controls. In short, fluorescent PNA probes (Panagene, Daejeon, 
Korea) were hybridized to the telomere sequence and the fluorescent signal was measured on 
a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA) and analyzed using the Kaluza 
software (figure 10) (Beckman Coulter, Brea, CA, USA). Fluorescent MESF-FITC beads 
(Bangs Laboratories, Fishers, IN, USA) were used and the fluorescent signal was quantified 
using the QuickCal v.2.3 data analysis program (Bangs Laboratories, Fishers, IN, USA). The 
TL was then calculated using the following formula: 
𝑇𝑒𝑙𝑜𝑚𝑒𝑟𝑒 𝑙𝑒𝑛𝑔𝑡ℎ, 𝑘𝐵 =
𝑀𝐸𝑆𝐹 𝑥 𝑛𝑏𝑎𝑠𝑒
𝑛𝑐ℎ𝑟 𝑥 1000
 
where MESF is the fluorescent intensity given by QuickCal v.2.3, nbase is the number of bases 
per PNA probe and nchr is the number of chromosomes in the species of the cells’ origin.  
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Figure 9. Chemical structure of: A) LY2784544, B) GRN163L. 
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3.5 RNA EXTRACTION AND QUANTITATIVE REAL-TIME PCR 
(PAPERS I, II & IV) 
Total RNA was isolated using Trizol (Life Technologies) and the concentration was measured 
with a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Reverse 
transcription was performed with a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Waltham, MA, USA). Quantitative real time polymerase chain reaction (qRT-
PCR) was performed in triplicate using SYBR Green PCR Master Mix (Life Technologies, 
Carlsbad, CA, USA) with QuantStudio 7 Flex Teal-Time PCR system (Applied Biosystems, 
Waltham, MA, USA). 
3.6 WESTERN BLOT (PAPERS I & IV) 
Whole cell protein was extracted from granulocytes using Trizol according to the 
manufacturer’s instructions (paper I) or from cultured cells using RIPA lysis buffer (paper 
IV). Protein concentrations were measured using a DC protein assay (Biorad, Hercules, CA, 
USA). Proteins were separated on SDS-PAGE gels and transferred to PVDF membranes. The 
membranes were blocked in milk and then probed with antibodies against POT-1, TIN-2, 
TPP-1, KLF4, SOCS3, MT1x and GSTP1, followed by anti-mouse, rabbit or goat antibodies 
Figure 10. Flow-FISH assessment of telomere length in blood cells from MPN patients. 
Left panel: Density plot with forward scatter on the x-axis and cell cycle stain with LDS 751 on the 
y-axis. Cell populations were gated as shown into three populations: (i) Calf thymocytes (red in the 
middle and right panels), (ii) lymphocytes (green in the middle and right panels) and (iii) 
granulocytes (blue in the middle and right panels). Middle panel: Whole blood sample hybridized 
without telomeric probe. Right panel: Whole blood sample hybridized with FITC-labeled telomeric 
probe. 
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conjugated with horse radish peroxidase. The signal was detected with enhanced 
chemiluminescent (ECL) substrate. β-actin was used as a loading control.  
3.7 TELOMERASE ACTIVITY ASSAY (PAPERS I & IV) 
Telomerase activity was assessed using the telomerase repeat amplification protocol (TRAP)-
ELISA kit (Roche, Basel, Switzerland). This method allows a semi-quantitative measurement 
of telomerase activity
136,137
. Briefly, the telomerase elongates the 3’ end of a biotin-labeled 
synthetic primer and the elongation product is then amplified with PCR. The amplified 
products are denatured and hybridized to digoxigenin (DIG)-conjugated detection probes 
specific to the telomeric sequence. The products are then affixed to a streptavidin-coated 
microplate by the biotin. Amplified products stuck to the microplate are then bound to 
antibodies against DIG, conjugated with horseradish peroxidase and the peroxidase 
substrate
136
. 
3.8 DNA EXTRACTION AND GENOTYPING OF TERT rs2736100 
(PAPER II) 
DNA was extracted from peripheral blood (Swedish and Chinese patients and Chinese 
controls) using QIAmp DNA blood kit (Qiagen, Hilden, Germany). DNA was extracted from 
saliva from Swedish healthy controls using Oragene saliva collection kit (DNA Genotek Inc., 
Ottawa, Canada)
43
. DNA concentration was measured with a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). TERT rs2736100 genotyping 
was performed using pre-designed TaqMan SNP genotyping assay kits on a QuantStudio 7 
flex system (Applied Biosystems, Waltham, MA, USA). The assay included negative controls 
and was run with the following protocol: 95°C for 10 min, followed by 40 cycles of 92°C for 
15s and 60°C for 1 min.  The genotyping success rate was >95%. 
3.9 WHOLE GENOME SEQUENCING (WGS) (PAPER III) 
Genomic DNA from the APL patient’s BM at initial diagnosis and relapse, and peripheral 
blood from when she was in CR were used. Libraries of qualified genomic DNA were 
prepared for paired-end analysis by the Illumina HiSeq 2000. After the generation of clusters 
of template DNA, they were sequenced by the Illumina HiSeq 2000 platform. Each sample 
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was >30-fold haploid coverage. After a strict QC test, the sequencing data were subjected to 
bioinformatics analysis. The raw sequencing data were filtered and then aligned using the 
Burrows-Wheeler Aligner. The 13 human genome build 37 (Hg19) was used as the reference 
genome for mapping. Then, the generated BWA files were processed by the SOAPsnp, 
SAMtools, BreakDancer and ANNOVAR to analyze and annotate the variants. In order to 
find the precise translocation sites of PML-RARα, the intrachromosomal translocation 
analysis of paired-end sequence data of initial and second APL samples was performed using 
BreakDancer
138
. First, all Maq-mapped reads within 3000bp of chromosomal locations of 
PML and RARα were extracted by SAMtools139. Then the data were analyzed for structural 
variants using BreakDancer.  
3.10 SOUTHERN BLOT FOR TELOMERE LENGTH ASSAY (PAPER 
III) 
Genomic DNA from BM and peripheral blood was digested overnight at 37°C with HinfI and 
RsaI restriction enzymes. The completely digested genomic DNA was separated on a 0.8 % 
agarose TAE gel and vacuum transferred to a Hybond-nylon membrane using 10 × SSC 
buffer. The membrane was air-dried and UV cross-linked. Hybridization of DNA fragments 
and chemiluminescent detection were performed using the TeloTAGGG Telomere Length 
Assay kit according to the manufacturer’s protocol (Roche, Basel, Switzerland). Briefly, the 
separated DNA fragments were hybridized to a DIG-labeled probe specific for the telomere 
sequence, followed by incubation with a DIG-specific antibody linked to alkaline phosphate 
(AP). The signal is then detected with a chemiluminescent substrate for AP. The 
chemiluminescence signal was detected in the Quantity One® Software (Biorad, Hercules, 
CA, USA) and the data was analyzed according to Roche’s instructions. 
3.11 ARRAY-COMPARATIVE GENOMIC HYBRIDIZATION (PAPER III) 
Array-comparative genomic hybridization (CGH) of DNA isolated from BM samples was 
performed using the platform from Oxford Gene Technology (Oxford, UK) with four arrays 
of 180K oligonucleotide probes (60-mer). This platform gave a complete genome-wide 
survey with an average resolution of 20-50 Kb. Hybridization was performed according to the 
manufacturer’s recommendation. The arrays were scanned on an Agilent Microarray Scanner 
and data was analyzed in the CytoSur Interpret Software (OGT, Oxford, UK). 
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3.12 MUTATIONAL ANALYSIS OF FLT3-ITD AND FLT3-D835 (PAPER 
III) 
DNA at first and second diagnosis of the APL patient was extracted from BM using QIAamp 
Blood & Cell Culture DNA Kit (QIAGEN, Hilden, Germany). FLT3-ITD and FLT3-D835 
mutations were studied qualitatively using the fragment length analysis method. PCR primers 
were fluorescently labeled with 6-FAM, NED or HEX. Amplified fragments were detected 
using Applied Biosystems 3130 XL and the length of each dye-labeled fragment was 
calculated by comparing it to a size standard using the GeneMapper software. 
3.13 COLONY FORMATION ASSAY (PAPER IV) 
Colony formation assay was performed in 6-well plates containing 500 HEL cells/well, 
seeded in Methocult H4100 (Stemcell Technologies, Vancouver, Canada) supplemented with 
RPMI1640 and incubated for 10 days at 37°C with 5% CO2. The number of colonies 
consisting of 25-50 cells and >50 cells were counted after 10 days of incubation.  
3.14 FLOW CYTOMETRY ANALYSIS OF CD34 FRACTION AND 
APOPTOSIS (PAPER IV) 
Cells were washed in PBS and blocked in mouse serum for 15 min. Cells were then incubated 
with APC anti-CD34 antibodies (BD Biosciences #555824) for 45 min at 4C. Apoptosis was 
measured using an Annexin V-FITC/7-AAD kit following the manufacturer’s protocol 
(Beckman Coulter, Brea, CA, USA). Annexin V is a protein with a high affinity for 
phosphatidylserine, a protein that is translocated from the inside of the plasma membrane to 
the outer side in an early stage of apoptosis
140
. 7-AAD is a fluorescent molecule which binds 
and stains DNA in cells with compromised plasma membrane. It is therefore often used as a 
viability staining
141
. 7-AAD alone can also be used as an apoptosis marker due to its partial 
uptake in apoptotic cells, giving a weaker fluorescent signal compared to dead cells
142
.    
3.15 LENTIVIRAL TRANSFECTION (PAPER IV) 
HEL cells were seeded at a density of 0.4  106/ml 24h prior to transduction. Lentiviral 
particles (Origene, Rockville, MD, USA (TL316853V)) were used at a multiplicity of 
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infection of 20 together with 5µg/ml Polybrene (Santa Cruz Biotechnologies, Dallas, TX, 
USA). Medium was changed 16h after transduction and selection with puromycin was started 
48h after transduction. In some experiments cells were sorted using a BD Influx (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA). 
3.16 WHOLE TRANSCRIPT EXPRESSION ANALYSIS 
Microarray analysis was performed using Affymetrix whole-transcript expression analysis 
and the WT assay gene ST 1.1 (Affymetrix, Santa Clara, CA, USA) in association with the 
Bioinformatics and Expression Analysis Core Facility (BEA), Karolinska Institutet. 
3.17 STATISTICAL ANALYSES 
The comparison of TL and mRNA expression of telomere binding proteins was made using 2-
tailed Student’s t-test (paper I). Age adjustment of telomere length was performed in 
Graphpad Prism 5 using the ANCOVA-based function “compare slopes and intercepts” 
(paper I). For correlation analyses Pearson’s correlation coefficient was generated using the 
correlation tool in Excel’s Analysis ToolPak add-in software. A t-value was generated using the 
following formula: 
 
 
The T-distribution calculation tool in Excel was then used to generate a P-value. For all 
calculations a two tailed test was used (Paper I). Differences in telomere length and mRNA 
expression of TERT among different genotypes of TERT rs2736100 were determined using 
Mann-Whitney U test (paper II). For comparison of genotype distributions of TERT rs2736100 in 
MPN patient and controls, Fisher’s exact test was used for generation of odds ratio (OR), 
confidence interval (CI) and P-value (paper II). When comparing the distribution of TERT 
rs2736100 variants in healthy populations in China and Europe, a Chi-square test was used (paper 
II). Results from TRAP, mRNA expression, colony formation assay and flow-FISH of TL were 
compared using the two-tailed Student’s t-test (paper IV). All analyses were performed in 
Graphpad Prism 5 if not stated otherwise. P-values <0.05 was considered statistically 
significant. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
 4.1.1 Telomere shortening in granulocytes from patients with 
Myeloproliferative neoplasms 
 The characteristics of the 81 patients with MPNs and the 43 healthy controls are presented in 
table 6. As MPNs affects the myeloid lineages, TL was determined using flow-FISH in both 
granulocytes and lymphoid cells in peripheral blood samples from patients and healthy 
controls. TL in granulocytes was significantly shorter in MPN patients than in healthy 
controls (mean ± SD: 7.27 kb ± 2.11 vs 8.66 kb ± 1.82, P < 0.001; figure 11). As previously 
reported
143
, TL was highly age-dependent in patients (r = -0.34, P <0.001). The significant 
difference in TL between patients and healthy controls remained after correcting for age (P = 
0.046). In contrast, there was no difference in TL between lymphoid cells in patients and in 
Characteristics MPN HC
N. of individuals 81 43
Sex
Male n. (%) 36 (44) 16 (37)
Female n. (%) 45 (56) 27 (63)
Age (years)
Median (range) 68 (25-106) 56 (16-84)
Mean ± SD 67 ±13 52 ± 18
Subtype
ET 24
PV 41
PMF 12
Unclassified 4
Positive 65
Negative 16
Median (range) 4 (1-36)
Mean ± SD 6.6 ± 6.9
Unknown (n. patients) 5
None 8
Hydroxyurea 50
Interferons 2
Other (Aspirin, warfarin, venesectio) 14
Unknown 7
MPN: myeloproliferative neoplasm; HC: healthy controls; ET: essential 
thrombocythemia; PV: polycythemia vera; PMF: primary myelofibrosis
Table 6. Summary of clinical features of patients with 
MPNs and demographics of healthy controls
JAK2
V617F
 status
Disease duration, years
Treatment n.
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healthy controls (mean ± SD: 8.38 kb ± 2.08 vs 8.67 kb ± 1.89, P = 0.437; figure 11). 
Furthermore, patients’ granulocytes exhibited significantly shorter TL compared to their own 
lymphoid cells (P = 0.001; figure 11), whereas no difference was seen between granulocytes 
and lymphoid cells in heathy controls. These results collectively suggest that accelerated 
telomere attrition was restricted to myeloid lineage cells in patients with MPNs. Significantly 
shorter granulocyte telomeres were seen in all subtypes of MPNs compared to controls before 
age-adjustment. However, after age adjustment only PV patients displayed a significant 
difference (P = 0.025). There was no difference in TL between subtypes. TL was not affected 
by sex, disease duration, treatment or JAK2
V617F
 status.  
4.1.2 Dysregulation of shelterin proteins in patients with Myeloproliferative 
Neoplasms 
After verifying that telomere shortening occurred in granulocytes of MPN patients, we sought 
to determine whether the expression of shelterin factors was altered in patient granulocytes. 
mRNA levels of the six shelterin proteins were analyzed using qRT-PCR. There were no 
differences in TRF1 or TRF2 mRNA expression between MPN patients and healthy controls. 
Granulocytes from MPN patients had a higher expression of POT1 (mean ± SD: 1.85 ± 0.62 
vs 1.15 ± 0.54, P < 0.001) and TIN2 (mean ± SD: 1.32 ± 0.35 vs 1.07 ± 0.33, P <0.001) 
compared to that in healthy controls. In contrast, RAP1 and TPP1 was lower in granulocytes 
from MPN patients compared to controls (mean ± SD: 0.69 ± 0.18 vs 1.01 ± 0.35, P <0.001 
and 0.83 ± 0.29 vs 1.0 ± 0.39, P <0.01 respectively). RAP1 mRNA levels were lower in all 
three MPN subtypes compared to healthy controls (P <0.001, <0.001, and =0.015 for ET, PV 
Figure 11. Telomere length (kb) in granulocytes (Granu) and lymphoid cells (Lymph) 
derived from patients with MPNs and healthy controls (HC). 
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and PMF, respectively), whereas TPP1 expression was significantly lower only in patients 
with PV compared to healthy individuals (P = 0.004). Moreover, TPP1 mRNA expression 
was only reduced in patients who had received HU, suggesting that the aberrant expression of 
TPP1 is secondary to treatment with HU. The mRNA expression of shelterins was not 
affected by age, sex or disease duration. Telomere length showed a significant negative 
correlation with POT1 mRNA expression (r = -0.28, P= 0.002), but was not associated with 
the expression of other shelterin proteins. The higher expression of POT1 and TIN2 and the 
lower expression of TPP1 were also confirmed at the protein level by Western blot (WB). No 
difference in RAP1 protein expression could be detected.  
4.1.3 POT1 expression is associated with JAK2V617F 
POT1 was the only shelterin protein that was expressed differently depending on the MPN 
patient’s JAK2V617F status (P = 0.04). Furthermore, POT1 mRNA tended to correlate with 
JAK2
V617F
 allele burden. However, the correlation was not statistically significant (P = 0.08), 
probably due to the rather limited number of patients. To determine whether the elevated 
POT1 expression was influenced by JAK2
V617F
 status we treated HEL cells with a JAK2 
inhibitor (LY2784544). JAK2-inhibition decreased the expression of POT1 mRNA to 
approximately half of the original level (P = 0.001). A slight decrease in the protein 
expression of POT1 was seen after JAK2 inhibition.  
4.1.4 Discussion 
Telomere shortening in MPN has been reported before
115,116
. It is reasonable to believe that 
excessive proliferation is one of the mechanisms causing telomere shortening, but all factors 
underlying telomere shortening in MPNs are still not understood. Both POT1 and TIN2 are 
known negative regulators of TL
12,144
, whereas TPP1 and RAP1 have telomere lengthening 
functions. Our findings of a higher expression of negative regulators and lower expression of 
positive regulators of TL support that dysregulation of the shelterin proteins contributes to the 
telomere shortening seen in MPNs. Understanding this mechanism is of great importance 
since patients with short telomeres are reported to be more prone to develop secondary MF 
and to transform to MDS and AML
115
. Our finding that TPP1 expression is lower in patients 
that received HU needs to be verified by mechanistic studies and its possible effect on MPN 
pathogenesis evaluated. Whether HU increases the risk of disease transformation is, as 
mentioned in the introduction, a point of contention
107
.  A telomerase inhibitor is in clinical 
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trials for PMF with promising preliminary results
100
. Given the telomere shortening and 
expression changes seen in patients with MPNs it is worth investigating if these factors can be 
used to predict a patients’ response to telomerase inhibition. 
Previous investigators report an elevated telomerase activity in the BM cells derived from 
patients with MPNs
115,118
. We analyzed the TERT mRNA expression in granulocytes and 
could not detect any differences between MPN patients and healthy controls. This finding 
suggests that telomerase is in general not activated in MPN cells. 
4.2 PAPER II 
4.2.1 Different TERT rs2736100 allele distributions in healthy Swedish and 
Chinese populations 
Genotyping of TERT rs2736100 was performed in healthy controls in Sweden (n = 756) and 
China (n = 101). The A-allele was more frequent in the Han Chinese population (57%) than in 
the Swedish population (47%) (P = 0.006). Healthy Chinese individuals also had more AA 
genotypes and less CC genotypes compared to the Swedish population (Table 7). To verify 
our finding, we collected genotyping data from previously published studies from China
145,146
 
and Europe
147,148
. The genotype distribution in published studies was very similar to our data 
for both Han Chinese and Caucasians. When pooling the studies we included a total of 2910 
and 1359 healthy individuals from China and Europe, respectively, finding that Europeans 
had a higher frequency of the C allele and a lower frequency of the A allele (48 vs 57% and 
52 vs 43% for A and C respectively, P <0.001, Table 7) 
 
Table 7. Published rs2736100 genotype distribution of healthy populations in China and Europe
Author N AA (%) AC (%) CC (%) A (%) C (%) Area Reference
Dahlström et al101 33 (32.7) 50 (49.5) 18 (17.8) 116 (57.4) 86 (42.6) North" This study
Yuan et al 289 86 (29.8) 144 (49.8) 59 (20.4) 316 (54.7) 262 (45.3) North" [145]
Wei et al 2520 814 (32.3) 1269 (50.4) 437 (17.3) 2897 (57.5) 2143 (42.5) South# [146]
Total 2910 933 (32.1)* 1463 (50.3)* 514 (17.6)* 3329 (57.2)* 2491 (42.8)*
Dahlström et al756 167 (22.1) 377 (49.9) 212 (28.0) 711 (47.0) 801 (53.0) Sweden This study
Jäger et al 202 47 (23.3) 88 (43.6) 67 (33.2) 182 (45.0) 222 (55.0) Italy [147]
Krahling et al 400 111 (27.8) 188 (47.0) 101 (25.2) 410 (51.3) 390 (48.7) Hungary [148]
Total 1358 325 (23.9)** 653 (48.0)** 380 (28.1)** 1303 (48.0)** 1413 (52.0)**
AA vs AC+CC AC vs AA+CC CC vs AA+AC C vs A
<0.001 0.106 <0.001 <0.001
OR and P- values generated using Chi-square test. "From Shandong area; #From Shanghai and Guangzhou areas
Europe
China
P- value (* vs **)
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4.2.2 TERT SNP rs2736100_C is a risk factor for myeloproliferative neoplasms 
in males 
Due to different genotype distributions in the healthy populations, we chose to analyze the 
Chinese and Swedish MPN patients separately. Both Chinese and Swedish MPN patients had 
a higher frequency of the rs2736100_C allele compared to their corresponding controls (both 
P = 0.004, table 8). The higher frequency of CC genotypes and C alleles was seen in all MPN 
subtypes, with no difference between them. Further analysis revealed that the higher 
frequency of the CC genotype and C allele was only present in male MPN patients, whereas 
no difference was seen between healthy women and women with MPNs. There was no 
difference in allele distributions between healthy men and women.  
 
4.2.3 TERT mRNA expression and telomere length in patients with 
myeloproliferative neoplasms carrying different TERT rs2736100 genotypes 
Patients bearing the TERT rs2736100_CC genotype displayed the highest TERT mRNA 
expression, with a significant difference between the AC and CC carrying patients (P = 0.024) 
(figure 12). The difference between the CC and AA variant was not significant, likely due to 
the small number of patients. No correlation was seen between TL and TERT rs2736100 
genotype (figure 12).  
Control Control
n. (%) n. (%) OR (95% CI) P value n. (%) n. (%) OR (95% CI) P value
756 (100) 126 (100) 101 (100) 101 (100)
A 711 (47.0) 94 (37.3) 1.0 (ref) 116 (57.4) 86 (42.6) 1.0 (ref)
C 801 (53.0) 158 (62.7) 1.49 (1.13-1.96) 0.004 86 (42.6) 116 (57.4) 1.82 (1.23-2.70) 0.004
AA 167 (22.1) 15 (11.9) 1.0 (ref) 33 (32.7) 17 (16.8) 1.0 (ref)
AC 377 (49.9) 64 (50.8) 1.89 (1.05-3.41) 0.034 50 (49.5) 52 (51.5) 2.02 (1.00-4.08) 0.057
CC 212 (28.0) 47 (37.3) 2.47 (1.33-4.57) 0.003 18 (17.8) 32 (31.7) 3.45 (1.52-7.85) 0.005
AA+AC 544 (72.0) 79 (62.7) 1.0 (ref) 83 (82.2) 69 (68.3) 1.0 (ref)
CC 212 (28.0) 47 (37.3) 1.53 (1.03-2.27) 0.044 18 (17.8) 32 (31.7) 2.14 (1.11-4.14) 0.033
AC+CC 589 (77.9) 111 (88.1) 1.0 (ref) 68 (67.3) 84 (83.2) 1.0 (ref)
AA 167 (22.1) 15 (11.9) 0.48 (0.27-0.84) 0.009 33 (32.7) 17 (16.8) 0.42 (0.21-0.81) 0.014
Significant P- values are shown in italic
OR and P- values generated using Fishers' exact test. 
MPN, Myeloproliferative Neoplasms; OR, Odds ratio; CI, Confidence interval
Genotypes
Table 8. Genotypes of TERT rs2736100 in MPN patients compared to healthy controls
Sweden China
MPN MPN
All
Alleles
rs2736100 genotype
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4.2.4 Discussion 
A number of research groups have recently reported an association between the TERT 
rs2736100_C allele and the risk of MPNs
119,120
. Previous studies were exclusively based on 
Caucasian populations, and in this study we found that the same association is also present in 
the Chinese population.  The frequency of the C allele was found to be higher in the healthy 
population in Sweden compared to China, which is corroborated by previously published 
studies from Europe and China. Interestingly, the incidence of MPNs is higher in Europe than 
in China, which might partly be explained by a difference in TERT rs2736100 variants. In this 
study, the risk of MPNs was associated with the C allele only in males, which has not been 
described before. Interestingly, female MPN patients have a better prognosis than men
149,150
. 
Some authors report that the shorter overall survival in men is caused by a higher frequency 
of secondary MF and AML transformation
150
, but others report that the increased risk of 
developing a secondary malignancy is not gender related
151
.  Therefore, further studies are 
needed to determine if there is an association between the TERT rs2736100 C allele and MPN 
transformation to MDS/AML.  
We found that patients with the CC genotype had a higher expression of TERT, which most 
likely results in a higher telomerase activity. The rs2736100 C allele has previously been 
linked to higher TERT expression and longer telomeres in both normal- and tumor cells
146
. 
Our results indicate that patients bearing the C allele may be able to better compensate for the 
telomere erosion seen in MPNs, an ability which potentially could help to maintain 
genetically stable cells. However, TERT also has other functions apart from telomere 
Figure 12. TERT mRNA expression and TL in Swedish MPN patients with different TERT 
rs2736100 genotypes. TERT mRNA expression was measured with qRT-PCR and TL was 
assessed using flow-FISH. * P <0.05 
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lengthening
55,57
, and has been implicated in cancer development and progression, and could 
therefore also potentially promote disease transformation in MPNs.  
4.3 PAPER III 
4.3.1 A unique patient with a very late relapse of acute promyelocytic leukemia 
A 42-year-old woman presented with fever, spontaneous bruising and fatigue in April 1994. 
She was diagnosed with APL by blood/BM analysis which showed the typical translocation 
(15;17)(q22;q12) and received ATRA and one course of cytarabine and daunorubicin as 
induction treatment, resulting in CR. After two subsequent consolidation courses of 
cytarabine and daunorubicin, she remained in good health until 2011, when she again 
presented with fatigue and bruising. She was again diagnosed with APL and obtained CR 
after induction treatment with ATRA, idarubicin and cytarabine. She received two 
consolidation courses with the same agents followed by two additional courses with ATRA 
and arsenic trioxide (ATO). 
4.3.2 Evolution of the patient’s acute promyelocytic leukemia-clone 
In order to clarify whether the patient had suffered a relapse, another de novo APL, or a 
secondary APL, we performed array-CGH and WGS on BM samples from 1994 and 2011. 
The array-CGH revealed genetic aberrations in both samples, with clear differences between 
the two (figure 13). The cells from the 1
st
 diagnosis had losses in chromosome 19, 3 and 20 
together with gain of material at chromosome 21. The cells at the 2
nd
 diagnosis had loss of a 
large part of the long arm of chromosome 9 and gain at chromosome 16.  WGS showed two 
different PML/RARα fusion sites (Chr17:38489469-Chr15:74316176 and Chr15:74316160-
Chr17:38489139) in both APL samples with a domination of the first fusion in both samples. 
Importantly, different mutations in FLT3 were seen in the two samples (FLT3-ITD and FLT3-
D835 respectively). 
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4.3.3 Telomere length at diagnosis of acute promyelocytic leukemia and in 
complete remission 
TL was measured using Southern blot in samples from the 1
st
 and 2
nd 
diagnosis and from the 
first CR. The average terminal restriction fragment length at 1
st
 diagnosis and 2
nd
 diagnosis 
was shorter (3.40kb, 3.27kb respectively) than that in CR (5.75 kb) (figure 14). 
Figure 14. Southern blot analysis of terminal restriction fragments, showing shorter 
telomeres at both acute promyelocytic leukemia diagnoses compared to when the patient 
was in complete remission.  
Figure 13. Array-CGH revealing different genetic aberrations at 1
st
 and 2
nd
 diagnosis. Left 
panel: regions with genetic loss and gains are presented in red and green respectively.  
First APL diagnosis Second APL diagnosis 
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4.3.4 Discussion 
The APL clone at second diagnosis had many genetic similarities with the clone at first 
diagnosis, such as identical gene fusion for the PML/RARα gene. However, the 1st and 2nd 
samples had significant differences in genetic aberrations and different mutations of FLT3. 
Based on these results, we believe that the 2
nd
 diagnosis was a true relapse from the initial 
APL. We hypothesize that the patient harbored the PML/RARα fusion gene, generating pre-
leukemic clones that were not transformed into an APL until the acquisition of the FLT3-ITD 
mutation. The leukemic clones were successfully eradicated with chemotherapy, whereas the 
ancestral PML/RARα bearing clone survived. Seventeen years later that clone gained a FLT3-
D835 mutation, leading to a second onset of APL (figure 15). To completely cure APL it is 
crucial to eradicate the leukemic stem cells (LSC). Evolution of non-eradicated LSC has been 
reported and relapse after conventional chemotherapy is associated with larger, more complex 
and more heterogeneous LSC populations
152
. 
ATO has been demonstrated to target the LSC in APL and thereby prevent relapses
153
. The 
patient received ATO when she obtained her second APL diagnosis and is currently in CR, 
but still under close molecular monitoring. The short telomeres seen in her tumor cells at 1
st
 
and 2
nd
 diagnosis are coherent with previous findings about critically short telomeres in 
AML
154
. It would be of importance to define the role of telomere maintenance in pre-
leukemic clones and whether this can affect the occurrence of further genetic aberrations 
causing the development of AML. 
 
 
Figure 15. Proposed evolution of the pre-leukemic clone in the patient. 
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4.4 PAPER IV 
 4.4.1 Reduced cell numbers and viability of HEL cells with JAK2 and 
telomerase inhibition 
Treatment with the JAK2 inhibitor LY2784544 initially reduced the cell number and viability 
in the erythroleukemia cell line HEL. However, the cells recovered after several weeks of 
treatment and after 9 weeks of treatment the viability was similar to that of control cells 
(figure 16). A similar pattern was seen for apoptosis, with a transient increase in apoptotic 
cells. Treatment with the telomerase inhibitor GRN163L also reduced the number of cells and 
their viability, but without any recovery over time. Importantly, a combination of LY2784544 
and GRN163L reduced the number of cells and their viability more than each treatment by 
itself, and no recovery was seen over time (figure 16).  
4.4.2 Accumulation of CD34 positive HEL cells following JAK2 inhibition 
The fraction of CD34 positive HEL cells was drastically increased after treatment with 
LY2784544, ranging from a few percent to >85% after 9 weeks of incubation (figure 17). In 
contrast, treatment with GRN163L reduced the number of CD34 positive cells, and even more 
importantly, a combination of LY2784544 and GRN16L did not increase the CD34 positive 
fraction. A colony formation assay confirmed that the increased fraction of CD34 positive 
cells after LY2784544 also gave rise to more and larger colonies.  
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Figure 16. Viability in HEL cells after treatment with LY2484544 and/or GRN163L.  
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HEL cells were also separated into CD34 negative and positive fractions before treatment 
with LY2784544. Here we found a lower viability and higher percentage of apoptotic cells 
after LY2784544 treatment in the CD34 negative population than in the positive population. 
An increase in the fraction of CD34 positive cells was seen after LY2784544 treatment in the 
CD34 negative population.  
4.4.3 Silencing KLF4 expression attenuated the LY2784544 mediated increase 
of CD34 positive cells 
An Affymetrix whole-transcript analysis was performed to find the mechanism underlying the 
accumulation of CD34 positive cells after JAK2 inhibition. Several genes were chosen for 
conformational PCR and WB. From these genes, KLF4 was chosen for further analysis, as it 
is known to regulate stem cells features. An increased expression of KLF4 after LY2784544 
treatment was confirmed both at the mRNA and protein level. Interestingly, KLF4 mRNA 
expression was significantly lower after treatment with a combination of LY2784544 and 
GRN163L compared to LY2784544 alone (figure 18A).   
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Figure 17. A) Fraction of CD34 positive HEL cells after LY2784544 treatment. B) 
Histograms of CD34 in cells after 7 weeks of incubation without (left) and with (right) 
LY2784544 treatment. 
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Figure 18. KLF4 mRNA expression in: A) HEL treated with LY2784544 and/or GRN163L 
B) HEL transduced with ShKLF4 or scrambled control treated with LY2784544. * 
indicates P-value <0.05, **<0.01, ***<0.001. 
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KLF4 was silenced using lentiviral transfection with ShKLF4 and the effect was confirmed by 
PCR and WB. The KLF4 mRNA expression was still increased in the ShRNA KLF4 
lentiviral transduced cells following LY2784544, but at much lower levels compared to the 
cells transduced with the scramble control ShRNA (figure 18B). Silencing KLF4 expression 
attenuated the LY2784544 mediated increase in CD34 positive cells, but did not block it 
completely.  
4.4.4 JAK2 inhibition down-regulates TERT expression and telomerase activity   
but elongates the telomeres in HEL cells 
A lower TERT mRNA expression and telomerase activity was seen in HEL cells following 
JAK2 inhibition with LY2784544 (figure 19A). Despite a lower TERT expression and 
telomerase activity, a significant increase in TL was seen after 7 and 9 weeks of incubation 
(figure 19B). In order to clarify if the longer telomeres observed after LY2784544 treatment 
were secondary to the increase in CD34 positive cells, TL was determined in CD34 negative- 
and positive populations, respectively. Indeed, the CD34 positive cells harbored significantly 
longer telomeres, but significantly longer telomeres were also observed in CD34 positive cells 
following 8 weeks of treatment with LY2784544 (figure 19D). Telomerase activity was 
reduced in both CD34 negative and positive populations at 4 and 8 weeks of treatment with 
LY2784544 (figure 19C).  
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4.4.5 Discussion  
Despite their effect on clinical symptoms JAK2 inhibitors have been reported to be unable to 
eradicate the disease clone in MPN and to have a minimal effect on JAK2
V617F
 allele burden 
in most patients
99,155
. Our findings support the notion that immature cells are less sensitive to 
JAK2 inhibition, resulting in an enrichment of these cells. This could explain the drugs’ 
incapacity to eliminate the disease-initiating clone. Our data also indicated that JAK2 
inhibition can induce a more premature state among the cells. The accumulation of CD34 
positive cells following treatment with LY2784544 can be of future importance in assisting us 
to understand potential side effects and clinical responses to this drug.  
0
0.2
0.4
0.6
0.8
1
1.2
Ctrl 1 w 4w 9w
* 
** 
** 
T
e
lo
m
e
ra
s
e
 a
c
ti
v
it
y
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0 4w
8w
T
e
lo
m
e
ra
s
e
 a
c
ti
v
it
y
 
0.5µM LY 
CD34 
− 
− 
+ 
+ 
+ 
− 
− 
+ 
* 
* 
0
2
4
6
8
10
12
14
16
18
20 4w
8w
* 
* 
0.5µM LY 
CD34 
− 
− 
+ 
+ 
+ 
− 
− 
+ 
T
e
lo
m
e
re
 l
e
n
g
th
, 
k
b
 
0
5
10
15
20
25
1w 4w 7w 9w
T
e
lo
m
e
re
 l
e
n
g
th
, 
k
b
 
** ** 
Ctrl 
0.5 µM 
LY 
Figure 19. A) Telomerase activity in HEL cells treated with LY2784544. B) Telomere length 
in HEL cells treated with LY2784544. C) Telomerase activity in CD34-sorted HEL cells 
treated with LY2784544. D) Telomere length in CD34-sorted HEL cells treated with 
LY2784544. 
A B 
C D 
36 
 
Interestingly, simultaneous treatment with GRN163L did not increase the number of CD34 
positive cells and had a larger effect on cell viability than any of the drugs used alone. The 
therapeutic effect of telomerase inhibition in MF is promising, but the treatment can also 
induce severe dose-dependent myelodepression in humans
100
. Targeted therapy in 
combination could therefore be beneficial by allowing lower doses of GRN163L with the 
same efficiency. Our data suggests that a combination of JAK2- and telomerase inhibition 
might be effective in the treatment of MPNs.  
KLF4 is one of the four transcription factors that together can be manipulated to generate 
induced pluripotent stem cells
156
. The role of KLF4 in hematopoiesis is not completely 
understood, but its ability to contribute to dedifferentiation supports a role in the maintenance 
of tissue-specific stem cells. Silencing KLF4 expression attenuated the LY2784544-mediated 
enrichment of CD34 positive cells, indicating that KLF4 upregulation is one mechanism 
affecting this enrichment. However, the enrichment was not completely blocked by KLF4 
repression, indicating that other unknown factors also play a role in this process. Other 
authors have previously demonstrated that the presence of JAK2
V617F
 downregulates KLF4 in 
MPN patients
157
. Collectively, this data suggests KLF4 as a potential therapeutic target in 
MPNs. 
In this study we found that JAK2 inhibition reduces telomerase activity. Other authors have 
previously reported that JAK/STAT signaling is a positive regulator of TERT by the direct 
binding of STAT3 and STAT5 to the TERT promoter
158
. It is possible that the general 
activation of the JAK/STAT signaling pathway in MPNs results in an increased TERT 
expression with a higher telomerase activity as a consequence. Previous studies have shown a 
higher telomerase activity in hematopoietic stem cells from MPN patients compared to 
healthy individuals
115
. Despite the lower telomerase activity, longer telomeres were seen after 
LY2784544 treatment, suggesting that they were elongated by a telomerase-independent 
mechanism. Further studies are needed to assess whether JAK2 inhibition results in telomere 
elongation in vivo in MPN cells and if so, its potential effect on MPN progression needs to be 
determined.  
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5 SUMMARY AND CONCLUSIONS 
Overall, the studies included in this thesis support that telomeres and telomerase play a role in 
the pathogenesis of MPNs and AML. More specifically: 
 
I. Patients with MPNs have shorter telomeres and dysregulation of shelterin proteins 
compared to healthy controls. Specifically, two shelterin proteins negatively regulating 
TL were overexpressed and two telomere lengthening shelterins were repressed in 
MPNs. This may be one of the mechanisms contributing to the telomere shortening 
seen in MPNs. TERT expression was not higher in granulocytes from MPN patients, 
suggesting that telomerase is not generally activated in MPN cells. 
II. The frequency of the TERT rs2736100 A and C allele is higher and lower, 
respectively, in the Han Chinese population than in the European population. This 
may contribute to the lower MPN incidence seen in China compared to that in Europe. 
The TERT rs2736100_CC genotype is associated with an increased risk of MPNs in 
both the Chinese and Swedish populations. This association was only seen in males, 
and the potential role of TERT rs2736100_CC genotype on disease progression needs 
to be elucidated. The TERT rs2736100_CC is associated with a higher TERT 
expression in MPN patients, but does not influence TL.  
III. We compared the genomic landscape of tumor cells from a patient’s 1st APL diagnosis 
to that of tumor cells from her 2
nd
 diagnosis of APL, after 17 years in CR. The 
identical breakpoints at the PML-RARα fusion in two APL samples suggest that the 
patient most likely suffered a relapse of her initial APL. However, different mutations 
in FLT3 and different genetic aberrations showed how the PML-RARα-carrying pre-
leukemic clone evolved while the patient was in complete remission, which provides 
profound insights into AML development.  
IV. LY2784544 treatment of HEL cells caused a transient reduction in the number of cells 
and their viability. CD34 negative cells are more sensitive to LY2784544, resulting in 
a dramatic increase in the number of CD34 positive cells. The accumulation of CD34 
positive cells can be abolished by simultaneous telomerase inhibition. The increase of 
the CD34 positive fraction after LY2784544 is mediated by an increased KLF4 
expression together with other unknown factors. LY2784544 treatment reduces TERT 
expression and telomerase activity, but increases TL in HEL cells. Collectively, this 
study proposes that combining JAK2 and telomerase inhibition may have a therapeutic 
benefit, and that KLF4 may be a potential therapeutic target in MPNs.  
  
38 
 
6 ACKNOWLEDGEMENTS 
Many people, co-workers, family and friends have supported me during my PhD studies and 
this work would not have been possible without them. Therefore, I would like to thank 
everyone that has helped me to finish my thesis. In particular I would like to thank: 
My main supervisor Dawei Xu for giving me the opportunity to do my PhD in his lab. Thank 
you for your exemplary guidance and encouragement and for helping me to develop my 
critical thinking and research skills. I also thank you for your patience when I prolonged my 
PhD with clinical work and travelling.  
My co-supervisor Magnus Björkholm, for your excellent supervision, support and 
inspiration. Thank you for always keeping your door open and sharing your profound 
knowledge in science, hematology, and life in general. My co-supervisor Åsa Rangert 
Derolf, for good advice and discussions in connection with my registration.  
Hans-Erik Claesson for always being positive and enthusiastic and making the hematology 
lab a warmer place. Last but not least, thank you for the magic! Jan Sjöberg for being a 
wonderful person and an inspiration in the research field.  
Meta Andersson for being a wonderful person who took me under her wings when I was new 
in the lab. Thank you for your warmth and kindness and for helping me a lot with my MPN 
project and teaching me the flow cytometer with great patience. Selina Parvin for great help 
with my project and for doing all practical work that makes the lab go around. But most of all, 
thank you for being a true friend in the lab with your positive and caring charisma and 
wonderful laughter. 
Monica Ekberg for sharing your profound knowledge in certain biomolecular methods and 
for your much appreciated company in the lab. Ann-Marie Andreasson for helping me with 
ordering and all other kinds of practical work in the lab.  
Malin Hultcrantz for helping me with the coordination in connection to the sampling of 
patients and for keeping an open door for discussions. Thank you for giving me the pictures of 
bone marrow taken from MPN patients. 
Research nurses Petra Janeld and Sarianna Cortes-Wiig for great collaboration with the 
sampling of MPN patients from the Hematology outpatient clinic.  
39 
 
All my fellow PhD students in the lab for the company and support; Hongya Han, Xiaolu 
Zhang, Bingnan Li, Tiantian Liu , Jingya Yu, Xiaotian Yuan,  Xiuming Liang and 
Yujiao Wu. I would also like to thank all the people working in the corridor at L8:00 for 
company, discussions and laughter. 
My co-authors; Mehran Gadheri, Ya Bin Wei, Catharina Lavebratt, Ping Li, Chengyun 
Zheng, Xidan Li for good collaboration and input on my project.  
My former supervisor at the department of Physiology and Pharmacology, Gunnar Schulte, 
for taking me in to your lab and trusting in me despite my limited research experience. It was 
you with your encouragement and outstanding supervision that got me hooked on preclinical 
research.   
My Mamma and Pappa, for your never ending support and unconditional love. No matter the 
challenge, I know that you are always there for me. 
My husband, Jonathan, for your endless love and for supporting me in everything I do. You 
are the best thing.   
Also, thanks to the rest of my family and friends who has made my PhD years much more 
fun and fruitful.  
This research was financially supported by the Adolf H.Lundin Charitable Foundation, the 
Swedish Research Council, Swedish Cancer Society, Cancer Society in Stockholm, 
Stockholm County Council and Gunnar Grimfors foundation. 
  
40 
 
7 REFERENCES 
1. Blackburn EH. Structure and function of telomeres. Nature. 1991;350(6319):569-573. 
2. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. 
Genes Dev. 2005;19(18):2100-2110. 
3. Longhese MP. DNA damage response at functional and dysfunctional telomeres. Genes 
Dev. 2008;22(2):125-140. 
4. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication 
problem and cell aging. J Mol Biol. 1992;225(4):951-960. 
5. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human 
fibroblasts. Nature. 1990;345(6274):458-460. 
6. Vaziri H, Schächter F, Uchida I, et al. Loss of telomeric DNA during aging of normal and 
trisomy 21 human lymphocytes. Am J Hum Genet. 1993;52(4):661-667. 
7. Romano GH, Harari Y, Yehuda T, et al. Environmental stresses disrupt telomere length 
homeostasis. PLoS Genet. 2013;9(9):e1003721. 
8. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am 
Geriatr Soc. 1997;45(4):482-488. 
9. Samassekou O, Gadji M, Drouin R, Yan J. Sizing the ends: normal length of human 
telomeres. Ann Anat. 2010;192(5):284-291. 
10. Lei M, Podell ER, Cech TR. Structure of human POT1 bound to telomeric single-
stranded DNA provides a model for chromosome end-protection. Nat Struct Mol Biol. 
2004;11(12):1223-1229. 
11. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM 
and ATR by TRF2 and POT1. Nature. 2007;448(7157):1068-1071. 
12. Loayza D, De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. 
Nature. 2003;423(6943):1013-1018. 
13. Karlseder J. Modern genome editing meets telomeres: the many functions of TPP1. 
Genes Dev. 2014;28(17):1857-1858. 
14. Sandin S, Rhodes D. Telomerase structure. Curr Opin Struct Biol. 2014;25:104-110. 
15. Cifuentes-Rojas C, Shippen DE. Telomerase regulation. Mutat Res. 2012;730(1-2):20-27. 
16. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of 
telomerase into normal human cells. Science. 1998;279(5349):349-352. 
17. Counter CM. The roles of telomeres and telomerase in cell life span. Mutat Res. 
1996;366(1):45-63. 
18. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer. 
2007;96(7):1020-1024. 
19. Ju Z, Jiang H, Jaworski M, et al. Telomere dysfunction induces environmental alterations 
limiting hematopoietic stem cell function and engraftment. Nat Med. 2007;13(6):742-
747. 
20. Wang Z, Zhu B, Zhang M, et al. Imputation and subset-based association analysis across 
different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L 
region on chromosome 5p15.33. Hum Mol Genet. 2014;23(24):6616-6633. 
21. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT 
promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 
2008;99(8):1528-1538. 
22. Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with c-Myc to activate transcription of 
the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 
2000;28(3):669-677. 
41 
 
23. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing 
variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia. 
2000;2(5):433-440. 
24. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human 
development is regulated by human telomerase reverse transcriptase (hTERT) 
transcription and by alternate splicing of hTERT transcripts. Cancer Res. 
1998;58(18):4168-4172. 
25. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol 
Biol Rev. 2002;66(3):407-425, table of contents. 
26. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR. Regulation of 
telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in 
normal and neoplastic ovary, endometrium and myometrium. Int J Cancer. 
2000;85(3):330-335. 
27. Klapper W, Shin T, Mattson MP. Differential regulation of telomerase activity and TERT 
expression during brain development in mice. J Neurosci Res. 2001;64(3):252-260. 
28. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the 
gene encoding the human telomerase reverse transcriptase (hTERT). Gene. 
1999;232(1):97-106. 
29. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC. DNA 
methylation analysis of the promoter region of the human telomerase reverse 
transcriptase (hTERT) gene. Cancer Res. 1999;59(24):6087-6090. 
30. Guilleret I, Benhattar J. Demethylation of the human telomerase catalytic subunit 
(hTERT) gene promoter reduced hTERT expression and telomerase activity and 
shortened telomeres. Exp Cell Res. 2003;289(2):326-334. 
31. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J. 
Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates 
with telomerase activity. Int J Cancer. 2002;101(4):335-341. 
32. Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and decrease 
in histone acetylation at the telomerase reverse transcriptase promoter during 
differentiation of HL60 cells. Proc Natl Acad Sci U S A. 2001;98(7):3826-3831. 
33. Wang S, Hu C, Zhu J. Transcriptional silencing of a novel hTERT reporter locus during 
in vitro differentiation of mouse embryonic stem cells. Mol Biol Cell. 2007;18(2):669-
677. 
34. Takakura M, Kyo S, Sowa Y, et al. Telomerase activation by histone deacetylase 
inhibitor in normal cells. Nucleic Acids Res. 2001;29(14):3006-3011. 
35. Blasco MA. The epigenetic regulation of mammalian telomeres. Nat Rev Genet. 
2007;8(4):299-309. 
36. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in 
immortal human cells without detectable telomerase activity. EMBO J. 
1995;14(17):4240-4248. 
37. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an 
alternative mechanism for maintaining telomere length in human tumors and tumor-
derived cell lines. Nat Med. 1997;3(11):1271-1274. 
38. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and 
implications. Nat Rev Genet. 2010;11(5):319-330. 
39. Henson JD, Reddel RR. Assaying and investigating Alternative Lengthening of 
Telomeres activity in human cells and cancers. FEBS Lett. 2010;584(17):3800-3811. 
40. Dilley RL, Greenberg RA. ALTernative Telomere Maintenance and Cancer. Trends 
Cancer. 2015;1(2):145-156. 
42 
 
41. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres 
in mammalian cells. Oncogene. 2002;21(4):598-610. 
42. Queisser A, Heeg S, Thaler M, von Werder A, Opitz OG. Inhibition of telomerase 
induces alternative lengthening of telomeres during human esophageal carcinogenesis. 
Cancer Genet. 2013;206(11):374-386. 
43. Wei YB, Martinsson L, Liu JJ, et al. hTERT genetic variation in depression. J Affect 
Disord. 2016;189:62-69. 
44. Schönland SO, Lopez C, Widmann T, et al. Premature telomeric loss in rheumatoid 
arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. 
Proc Natl Acad Sci U S A. 2003;100(23):13471-13476. 
45. Newbold RF. The significance of telomerase activation and cellular immortalization in 
human cancer. Mutagenesis. 2002;17(6):539-550. 
46. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 
1997;33(5):787-791. 
47. Prescott J, Wentzensen IM, Savage SA, De Vivo I. Epidemiologic evidence for a role of 
telomere dysfunction in cancer etiology. Mutat Res. 2012;730(1-2):75-84. 
48. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic 
transformation of primary mammary epithelial cells. Genes Dev. 2001;15(1):50-65. 
49. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. 
Creation of human tumour cells with defined genetic elements. Nature. 
1999;400(6743):464-468. 
50. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically 
tractable model of human glioma formation. Cancer Res. 2001;61(9):3556-3560. 
51. Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human 
fibroblasts immortalized with telomerase. Nat Genet. 1999;21(1):115-118. 
52. Jiang XR, Jimenez G, Chang E, et al. Telomerase expression in human somatic cells does 
not induce changes associated with a transformed phenotype. Nat Genet. 1999;21(1):111-
114. 
53. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol. 
2011;21(6):349-353. 
54. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a 
telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002;99(20):12606-
12611. 
55. Liu Z, Li Q, Li K, et al. Telomerase reverse transcriptase promotes epithelial-
mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 
2013;32(36):4203-4213. 
56. Gorbunova V, Seluanov A, Pereira-Smith OM. Expression of human telomerase 
(hTERT) does not prevent stress-induced senescence in normal human fibroblasts but 
protects the cells from stress-induced apoptosis and necrosis. J Biol Chem. 
2002;277(41):38540-38549. 
57. Ci X, Li B, Ma X, et al. Bortezomib-mediated down-regulation of telomerase and 
disruption of telomere homeostasis contributes to apoptosis of malignant cells. 
Oncotarget. 2015;6(35):38079-38092. 
58. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic 
melanoma. Science. 2013;339(6122):959-961. 
59. Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial 
cutaneous malignant melanoma. Nat Genet. 2014;46(5):482-486. 
60. Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants 
predispose to familial melanoma. Nat Genet. 2014;46(5):478-481. 
43 
 
61. Guo Y, Kartawinata M, Li J, et al. Inherited bone marrow failure associated with 
germline mutation of ACD, the gene encoding telomere protein TPP1. Blood. 
2014;124(18):2767-2774. 
62. Michiels JJ, Berneman Z, Schroyens W, De Raeve H. Changing concepts of diagnostic 
criteria of myeloproliferative disorders and the molecular etiology and classification of 
myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. 
Acta Haematol. 2015;133(1):36-51. 
63. Hultcrantz M, Andersson TM-L, Landgren OM, et al. A Population-Based Study of 
Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012. 
American society of hematology 57th annual meeting and exposition. Orlando, FL; 2015. 
64. http://haodf.health.sohu.com/disease/zhenxinghongxibaozengduozheng/jieshao.htm. Vol. 
2016; 2009. 
65. Johansson P, Kutti J, Andréasson B, et al. Trends in the incidence of chronic Philadelphia 
chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, 
during 1983-99. J Intern Med. 2004;256(2):161-165. 
66. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J 
Haematol. 1992;48(1):20-26. 
67. Melo JV, Goldman JM. Myeloproliferative disorders. Berlin Heidelberg: Springer; 2007. 
68. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) 
classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302. 
69. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: 
the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. 
Leukemia. 2008;22(1):14-22. 
70. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox 
of platelet activation and impaired function: platelet-von Willebrand factor interactions, 
and the etiology of thrombotic and hemorrhagic manifestations in essential 
thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32(6):589-604. 
71. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, 
and treatment. Annu Rev Med. 2009;60:233-245. 
72. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary 
myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981-2987. 
73. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in 
myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. 
74. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 
in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with 
myelofibrosis. Cancer Cell. 2005;7(4):387-397. 
75. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to 
constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. 
76. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 
2004;117(Pt 8):1281-1283. 
77. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary 
diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6(11):627-637. 
78. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 
617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 
Blood. 2007;110(3):840-846. 
79. Haider M, Gangat N, Lasho T, et al. Validation of the revised International Prognostic 
Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo 
Clinic patients. Am J Hematol. 2016;91(4):390-394. 
44 
 
80. Campbell PJ, Griesshammer M, Döhner K, et al. V617F mutation in JAK2 is associated 
with poorer survival in idiopathic myelofibrosis. Blood. 2006;107(5):2098-2100. 
81. Vannucchi AM, Pieri L, Guglielmelli P. JAK2 Allele Burden in the Myeloproliferative 
Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. Ther Adv 
Hematol. 2011;2(1):21-32. 
82. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 
(V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686-1689. 
83. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and 
idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. 
84. Schnittger S, Bacher U, Haferlach C, et al. Detection of JAK2 exon 12 mutations in 15 
patients with JAK2V617F negative polycythemia vera. Haematologica. 2009;94(3):414-
418. 
85. Akpınar TS, Hançer VS, Nalçacı M, Diz-Küçükkaya R. MPL W515L/K Mutations in 
Chronic Myeloproliferative Neoplasms. Turk J Haematol. 2013;30(1):8-12. 
86. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in 
myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390. 
87. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative 
neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405. 
88. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations 
in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 
2014;124(15):2465-2466. 
89. Santos FP, Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in 
patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 
2012;12(9):1098-1109. 
90. Abdel-Wahab O, Pardanani A, Bernard OA, et al. Unraveling the genetic underpinnings 
of myeloproliferative neoplasms and understanding their effect on disease course and 
response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J 
Hematol. 2012;87(5):562-568. 
91. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. 
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant 
myeloid diseases. J Hematol Oncol. 2012;5:12. 
92. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival 
in myelofibrosis. Blood. 2011;118(19):5227-5234. 
93. Hussein K, Huang J, Lasho T, et al. Karyotype complements the International Prognostic 
Scoring System for primary myelofibrosis. Eur J Haematol. 2009;82(4):255-259. 
94. Gangat N, Strand J, Lasho TL, et al. Cytogenetic studies at diagnosis in polycythemia 
vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol. 2008;80(3):197-
200. 
95. Gangat N, Tefferi A, Thanarajasingam G, et al. Cytogenetic abnormalities in essential 
thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 
2009;83(1):17-21. 
96. Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C. Distribution of 
cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative 
myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol. 
2009;88(12):1207-1213. 
97. Nordic Myeloproliferative Neoplasm Study Group: Nordic guidelines on the diagnosis 
and treatment of patients with Myeloproliferative Neoplasms. Sweden  2013. 
45 
 
98. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of 
long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with 
myelofibrosis. Blood. 2015;126(13):1551-1554. 
99. Angona A, Alvarez-Larrán A, Bellosillo B, Longarón R, Fernández-Rodríguez C, Besses 
C. Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in 
patients treated with ruxolitinib. Br J Haematol. 2016;172(4):639-642. 
100. Tefferi A, Lasho TL, Begna KH, et al. A Pilot Study of the Telomerase Inhibitor 
Imetelstat for Myelofibrosis. N Engl J Med. 2015;373(10):908-919. 
101. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia 
vera and essential thrombocythemia: a literature review of incidence and risk factors. 
Blood Cancer J. 2015;5:e366. 
102. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for 
transformation to acute myeloid leukemia and myelodysplastic syndromes in 
myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410-2415. 
103. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid 
leukemia with a complex karyotype. Semin Oncol. 2008;35(4):365-377. 
104. Milosevic JD, Puda A, Malcovati L, et al. Clinical significance of genetic aberrations in 
secondary acute myeloid leukemia. Am J Hematol. 2012;87(11):1010-1016. 
105. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in 
polycythemia vera associated with chlorambucil therapy. N Engl J Med. 
1981;304(8):441-447. 
106. Radaelli F, Onida F, Rossi FG, et al. Second malignancies in essential thrombocythemia 
(ET): a retrospective analysis of 331 patients with long-term follow-up from a single 
institution. Hematology. 2008;13(4):195-202. 
107. Björkholm M, Hultcrantz M, Derolf Å. Leukemic transformation in myeloproliferative 
neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol. 2014;27(2):141-
153. 
108. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict 
leukemic transformation and shortened survival: clinical evidence for leukemogenic 
collaboration with JAK2V617F. Leukemia. 2012;26(3):475-480. 
109. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that 
convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-
452. 
110. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic 
transformation. N Engl J Med. 2011;364(5):488-490. 
111. Mascarenhas J. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic 
Transformation of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 
2016;16 Suppl:S124-129. 
112. Rossi D, Deambrogi C, Capello D, et al. JAK2 V617F mutation in leukaemic 
transformation of philadelphia-negative chronic myeloproliferative disorders. Br J 
Haematol. 2006;135(2):267-268. 
113. Shirane S, Araki M, Morishita S, et al. Consequences of the JAK2V617F allele burden 
for the prediction of transformation into myelofibrosis from polycythemia vera and 
essential thrombocythemia. Int J Hematol. 2015;101(2):148-153. 
114. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-
V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F 
mutation. Blood. 2007;110(1):375-379. 
46 
 
115. Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere's length and 
telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. 
Leuk Res. 2011;35(4):459-464. 
116. Bernard L, Belisle C, Mollica L, et al. Telomere length is severely and similarly reduced 
in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia. 
2009;23(2):287-291. 
117. Elena C, Rumi E, Portolan M, Della Porta MG, Pascutto C, Passamonti F. Flow-FISH 
evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 
Haematologica. 2011;96(8):1236-1238. 
118. Kim M, Oh B, Kim TY, et al. Elevated telomerase activity in essential thrombocythemia 
with extreme thrombocytosis. Clin Biochem. 2014;47(6):389-392. 
119. Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant 
rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 
2014;28(6):1371-1374. 
120. Trifa AP, Bănescu C, Tevet M, et al. TERT rs2736100 A>C SNP and JAK2 46/1 
haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated 
myeloproliferative neoplasms - a multicentric study on 529 patients. Br J Haematol. 
2016. 
121. Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 
2016;2:16010. 
122. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute 
leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 
1976;33(4):451-458. 
123. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world 
data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. 
Blood. 2009;113(18):4179-4187. 
124. Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J 
Hematol Oncol. 2011;4:36. 
125. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum 
Genet. 2002;3:179-198. 
126. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a 
cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-5603. 
127. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal 
change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549-550. 
128. Grimwade D, Gorman P, Duprez E, et al. Characterization of cryptic rearrangements and 
variant translocations in acute promyelocytic leukemia. Blood. 1997;90(12):4876-4885. 
129. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with 
spontaneous and induced globin expression. Science. 1982;216(4551):1233-1235. 
130. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase 
mutation in cell lines derived from myeloproliferative disorders. Leukemia. 
2006;20(3):471-476. 
131. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in 
cancers and in myeloid malignancies other than the classic myeloproliferative disorders. 
Blood. 2005;106(8):2920-2921. 
132. Ma L, Zhao B, Walgren RA, et al. Efficacy of LY2784544, a Small Molecule Inhibitor 
Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy 
Models. 52nd Annual   Meeting   of the   American Society of Hematology. Orlando, 
Florida, USA; 2010. 
47 
 
133. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom 
Assessment Form (MPN-SAF): international prospective validation and reliability trial in 
402 patients. Blood. 2011;118(2):401-408. 
134. Verstovsek S, Mesa RA, Kloeker Rhoades S, et al. Phase I Study of the JAK2 V617F 
Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), 
and Essential Thrombocythemia (ET). Blood. 2011;118(21):2814. 
135. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM. Flow cytometry and FISH to measure 
the average length of telomeres (flow FISH). Nat Protoc. 2006;1(5):2365-2376. 
136. Xin H. Telomeric repeat amplification protocol: measuring the activity of the telomerase. 
Methods Mol Biol. 2011;735:107-111. 
137. Skvortsov DA, Zvereva ME, Shpanchenko OV, Dontsova OA. Assays for detection of 
telomerase activity. Acta Naturae. 2011;3(1):48-68. 
138. Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an algorithm for high-resolution 
mapping of genomic structural variation. Nat Methods. 2009;6(9):677-681. 
139. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and 
SAMtools. Bioinformatics. 2009;25(16):2078-2079. 
140. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic 
cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39-51. 
141. O'Brien MC, Bolton WE. Comparison of cell viability probes compatible with fixation 
and permeabilization for combined surface and intracellular staining in flow cytometry. 
Cytometry. 1995;19(3):243-255. 
142. Schmid I, Uittenbogaart CH, Keld B, Giorgi JV. A rapid method for measuring apoptosis 
and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods. 
1994;170(2):145-157. 
143. Sanders JL, Newman AB. Telomere length in epidemiology: a biomarker of aging, age-
related disease, both, or neither? Epidemiol Rev. 2013;35:112-131. 
144. Kim SH, Kaminker P, Campisi J. TIN2, a new regulator of telomere length in human 
cells. Nat Genet. 1999;23(4):405-412. 
145. Yuan X, Meng Y, Li P, et al. The association between the TERT rs2736100 AC genotype 
and reduced risk of upper tract urothelial carcinomas in a Han Chinese population. 
Oncotarget. 2016. 
146. Wei R, Cao L, Pu H, et al. TERT Polymorphism rs2736100-C Is Associated with EGFR 
Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. 2015;21(22):5173-
5180. 
147. Jäger R, Harutyunyan AS, Rumi E, et al. Common germline variation at the TERT locus 
contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol. 
2014;89(12):1107-1110. 
148. Krahling T, Balassa K, Kiss KP, et al. Co-occurrence of Myeloproliferative Neoplasms 
and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the 
Common TERT Polymorphism rs2736100. Cancer Epidemiol Biomarkers Prev. 
2016;25(1):98-104. 
149. Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients 
with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a 
population-based study. J Clin Oncol. 2012;30(24):2995-3001. 
150. Stein B, Spivak JL, Moliterno AR. Gender Is a Core Modifier of Disease Outcomes and 
Survival in the MPN. American Society of Hematology, 57th annual meeting and 
exposition. Orlando; 2015. 
48 
 
151. Ravn Landtblom A, Bower H, Andersson TM-L, et al. Increased Risk of Second 
Malignancies in Patients with Myeloproliferative Neoplasms Diagnosed in Sweden 1973-
2009 - A population-based Cohort Study of 9,379 Patients. European Hematology 
Association 21st Congress. Copenhagen, Denmark; 2016. 
152. Ho TC, LaMere M, Stevens BM, et al. Evolution of acute myelogenous leukemia stem 
cell properties after treatment and progression. Blood. 2016;128(13):1671-1678. 
153. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic 
leukemia. Leukemia. 2012;26(8):1743-1751. 
154. Swiggers SJ, Kuijpers MA, de Cort MJ, Beverloo HB, Zijlmans JM. Critically short 
telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes 
Chromosomes Cancer. 2006;45(3):247-256. 
155. Wang X, Ye F, Tripodi J, et al. JAK2 inhibitors do not affect stem cells present in the 
spleens of patients with myelofibrosis. Blood. 2014;124(19):2987-2995. 
156. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. 
157. Berkofsky-Fessler W, Buzzai M, Kim MK, et al. Transcriptional profiling of 
polycythemia vera identifies gene expression patterns both dependent and independent 
from the action of JAK2V617F. Clin Cancer Res. 2010;16(17):4339-4352. 
158. Yamada O, Kawauchi K. The role of the JAK-STAT pathway and related signal cascades 
in telomerase activation during the development of hematologic malignancies. JAKSTAT. 
2013;2(4):e25256. 
 
 
